心力衰竭临床试验中的子组和特殊人群:来自HFC-ARC专家共识小组的见解
Vanessa Blumer1, Biykem Bozkurt2, Marvin A Konstam3
1Inova Schar Heart and Vascular, Falls Church, Virginia, USA.
JACC. Heart failure
|January 6, 2026
概括
为改善临床试验设计和个性化治疗,建议对心力衰竭 (HF) 亚组进行标准化定义和终点. 这提高了研究准确性和HF管理中的患者结果.
科学领域:
- 心脏病学 心脏病学
- 临床试验 临床试验
- 遗传学 是一个遗传学.
背景情况:
- 心力衰竭 (HF) 管理需要在临床试验中进行子组分析,以更好地做出决策.
- 高频研究结果的异质性需要标准化的方法.
- 专家合作涉及学术界,工业界,FDA和患者代表.
研究的目的:
- 在临床试验中,为HF子组和特殊群体提出标准化定义和终点.
- 提高HF临床研究的精度,有效性和适用性.
- 促进对临床试验结果的个性化解释.
主要方法:
- 由心力衰竭协作室和学术研究联盟合作开发定义和终点.
- 专注于大规模试验中子组分析的方法考虑.
- 对遗传性心肌病的基因疗法的探索.
主要成果:
- 建议对HF子组和特殊群体的标准化定义和终点.
- 突出了解释子组分析和确定异质性的最佳实践.
- 强调需要验证产生假设的子组发现.
结论:
- 建议在临床试验设计方面采用有条不的方法,优先考虑子组识别和统计严谨性.
- 标准化的定义和终点将提高高频率试验结果的可靠性和临床相关性.
- 该框架旨在推进个性化和有效的HF治疗,改善患者的治疗结果.
更多相关视频
相关概念视频
Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
Heart Failure VI: Adjunct Therapies
246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
Heart Failure IV: Classification and Diagnostic Evaluation
313
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
313
Heart Failure III: Clinical Manifestations
465
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
465
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Pathophysiology of Heart Failure
2.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.8K


